Deep optimized generation for antimicrobial peptide discovery
The DOG-AMP project aims to revolutionize antimicrobial peptide discovery using advanced deep optimized generation methods to combat antibiotic resistance effectively.
Projectdetails
Introduction
The DOG-AMP project will develop cutting-edge methods for Deep Optimized Generation (DOG) and use them to transform the emerging field of AntiMicrobial Peptide (AMP) discovery.
Background
Continuous overuse of antibiotics fuels the outgrowth and spread of multi-drug resistant microbial strains. Increasing antimicrobial resistance is already a major health and economic hazard, and is expected to account for 10 million deaths globally per year by 2050, exceeding deaths caused by cancer.
Importance of AMPs
AMPs are short peptides that can actively and selectively kill antibiotic-resistant pathogens, and as such are considered the most promising strategy for fighting antimicrobial resistance. Still, intensive research on AMP did not translate to their success in the clinic, mostly due to their lower activity and safety compared to existing antibiotics.
Objectives of the DOG-AMP Project
Deep optimized generation has the potential to radically advance AMP discovery, but only once unsolved problems are attacked and open research directions in this area are further explored to reach three major objectives of the DOG-AMP project:
-
Develop a novel model, geared for deep optimized generation, combining the variational autoencoder framework with probabilistic modeling and algorithms for Pareto (conflicting multi-target) optimization, dealing with data scarcity and bias, generation diversity, and model interpretability.
-
Combine the deep optimized generation model into a framework tailored for the specific needs of AMP design, e.g., accounting for AMP clustering, or conflicting features that make AMPs active or toxic.
-
Apply the newly developed framework to explore and navigate the space of peptides to select and experimentally validate the best candidates that will supersede existing AMPs and antibiotics in their activity against hazardous microbes and safety.
Potential Impact
DOG-AMP has the potential to bring breakthroughs in the broad research areas of deep generative modeling, sequence optimization, and AMP discovery.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.998.471 |
Totale projectbegroting | € 1.998.471 |
Tijdlijn
Startdatum | 1-5-2024 |
Einddatum | 30-4-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBHpenvoerder
- UNIWERSYTET WARSZAWSKI
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Deep learning analysis of imaging and metabolomic data to accelerate antibiotic discovery against antimicrobial resistanceAI4AMR aims to revolutionize antibiotic discovery by using advanced AI and multi-dimensional data analysis to identify novel antibiotics and their mechanisms of action against antimicrobial resistance. | ERC Synergy ... | € 10.968.734 | 2025 | Details |
Scalable Microbial Metabolite Discovery Through Synthetic BiologyThis project aims to enhance the discovery of microbial secondary metabolites by developing a scalable heterologous expression platform to access untapped biosynthetic genes for drug development. | ERC Starting... | € 1.490.250 | 2024 | Details |
Bacteriocins from interbacterial warfare as antibiotic alternativeBACtheWINNER aims to develop novel antimicrobials from bacteriocins through advanced bioengineering and molecular genetics to combat antimicrobial resistance and improve human and animal health. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Automated, miniaturized and accelerated drug discovery: AMADEUSAMADEUS is an automated platform for rapid, sustainable drug discovery that synthesizes thousands of small molecules daily, optimizing processes through AI to reduce costs and enhance accessibility. | ERC Advanced... | € 3.409.401 | 2024 | Details |
Harnessing Specialized Metabolism from AnaerobesThe AnoxyGen project aims to explore and harness the unique biosynthetic capabilities of anaerobic bacteria to discover novel metabolites and enhance biotechnological applications for health and ecology. | ERC Advanced... | € 2.499.859 | 2025 | Details |
Deep learning analysis of imaging and metabolomic data to accelerate antibiotic discovery against antimicrobial resistance
AI4AMR aims to revolutionize antibiotic discovery by using advanced AI and multi-dimensional data analysis to identify novel antibiotics and their mechanisms of action against antimicrobial resistance.
Scalable Microbial Metabolite Discovery Through Synthetic Biology
This project aims to enhance the discovery of microbial secondary metabolites by developing a scalable heterologous expression platform to access untapped biosynthetic genes for drug development.
Bacteriocins from interbacterial warfare as antibiotic alternative
BACtheWINNER aims to develop novel antimicrobials from bacteriocins through advanced bioengineering and molecular genetics to combat antimicrobial resistance and improve human and animal health.
Automated, miniaturized and accelerated drug discovery: AMADEUS
AMADEUS is an automated platform for rapid, sustainable drug discovery that synthesizes thousands of small molecules daily, optimizing processes through AI to reduce costs and enhance accessibility.
Harnessing Specialized Metabolism from Anaerobes
The AnoxyGen project aims to explore and harness the unique biosynthetic capabilities of anaerobic bacteria to discover novel metabolites and enhance biotechnological applications for health and ecology.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Pharmaco-modulation of epithelia for induction of antimicrobial peptide expression: a disruptive approach to fight antibiotic resistanceMaxImmun aims to develop innovative molecules that enhance antimicrobial peptides to combat infections and antibiotic resistance, progressing towards clinical trials. | EIC Pathfinder | € 3.194.450 | 2024 | Details |
Targeted Nano-formulations for Treatment of MRSA: A multicomponent platform for nano-formulated treatment of resistant microbial infectionsLeadToTreat aims to develop targeted nano-formulations for treating MRSA infections by co-delivering novel low-drugability compounds and synergistic antibiotic combinations. | EIC Pathfinder | € 2.665.564 | 2022 | Details |
Pharmaco-modulation of epithelia for induction of antimicrobial peptide expression: a disruptive approach to fight antibiotic resistance
MaxImmun aims to develop innovative molecules that enhance antimicrobial peptides to combat infections and antibiotic resistance, progressing towards clinical trials.
Targeted Nano-formulations for Treatment of MRSA: A multicomponent platform for nano-formulated treatment of resistant microbial infections
LeadToTreat aims to develop targeted nano-formulations for treating MRSA infections by co-delivering novel low-drugability compounds and synergistic antibiotic combinations.